Cetuximab, a chimeric IgG1 antibody against EGFR, can evoke a T-cell-mediated anti-tumor immune response and stimulate NK-mediated antibody-dependent cellular cytotoxicity, independently of RAS mutational status [50]. Here, EGFR is linked to neoplasm.